Specials Laboratory to supply clinical trials service to UK hospitals

Published: 29-Mar-2010

New service aims to meet the product manufacturing needs of NHS-based clinical trials

Hospitals across the UK will be able to take advantage of a new service aimed at meeting the product manufacturing needs of NHS-based clinical trials.

The Specials Laboratory, based in Northumberland, is to specialise in the supply of non-sterile products for use in small-scale clinical studies direct to hospitals after the specialist firm was licensed for the manufacture of investigational medicinal products (IMPs).

The new IMP service will assist clinical trial pharmacists and technicians, university medical schools and research doctors.

Operating from three MHRA-approved facilities, the company complies with current Good Manufacturing Practice (cGMP) and provides in-house Quality Person (QP) release, which will ensure products delivered to hospitals will be made to the highest possible quality standards.

‘Our quality-led manufacturing heritage allows us to produce virtually any non-sterile dosage form,’ said Robert Sludden, Quality and Technical Services Manager at The Specials Laboratory.

‘The company is also able to offer customers an experienced technical team that includes several pharmacists, senior pharmacy technicians and QPs – many with an extensive NHS background.’

With more hospitals opting to subcontract their IMP manufacturing needs, The Specials Laboratory is looking to build relationships with relevant NHS departments by offering to be their outsourced manufacturing partner supplying products for smaller clinical trials.

‘Hospital departments will be able to source a wide range of products from The Specials Laboratory for their IMP manufacturing requirements, including oral liquids, capsules, sachets, ointments, creams, ear and nasal drops, enema solutions, suppositories and pessaries,' added Sludden.

Set-up over a decade ago, The Specials Laboratory employs around 130 people and is a leading UK manufacturer of unlicensed medicines, which are bespoke for individual patients and supplied to community and hospital pharmacists and doctors.

See more

You may also like

Manufacturing

PCCA buys the specials business and Arjun Products from UDG Healthcare for £23.5m

Read more
Deal includes The Specials Laboratory and Craig & Hayward in Northumberland, UK

Trending Articles

  1. Pfizer and BioNTech’s COMIRNATY COVID-19 vaccine wins FDA approval for seniors and high-risk individuals The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies
  2. Indena and TCG GreenChem join forces to advance next-generation ADC technologies Indena and TCG GreenChem are pleased to announce a new strategic collaboration aimed at accelerating the development of innovative and market-ready payload-linkers: the key component of antibody-drug conjugates (ADCs)
  3. SGD Pharma acquires Alphial Srl in a strategic step forward SGD Pharma is pleased to announce an agreement with Italian Private Equity firm Entangled Capital to acquire Alphial Srl, a leading producer of tubular vials and ampoules headquartered in Italy
  4. When the chemistry is right: Vetter expands capacities with a pure water generator from Pharmatec The production of injectable active pharmaceutical ingredients (APIs) is a highly complex process that leaves no room for error
  5. Meet Navetta: new approach to safety testing of drugs and particles Turn inhalation research upside down

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

PCCA buys the specials business and Arjun Products from UDG Healthcare for £23.5m

Deal includes The Specials Laboratory and Craig & Hayward in Northumberland, UK
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Autoinjector platforms: optimising device selection and unlocking manufacturing efficiency for injectable pipelines

Owing to ageing populations, the increased prevalence of chronic disease and additional pressure on global healthcare systems, among other factors, the market for drug delivery devices for self-administration (autoinjectors) is growing
Ingredients

Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt

Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence

OMass and Genentech to develop and commercialise therapies for inflammatory bowel disease

The collaboration leverages OMass’ Odyssion platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Debunking the myths of HPMC adoption

Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
Subscribe now